{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:31:20Z","timestamp":1785465080334,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11596-023-2801-y","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T04:24:29Z","timestamp":1699676669000},"page":"1183-1194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rifaximin Prevents Intestinal Barrier Dysfunction and Alleviates Liver Injury in MCT-induced HSOS Mice"],"prefix":"10.1007","volume":"43","author":[{"given":"Yan-yun","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-lin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-kuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"issue":"7","key":"2801_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant, 2016,51(7):906\u2013912","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2801_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant, 2016,51(3):403\u2013409","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2801_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol, 2013,163(4):444\u2013457","journal-title":"Br J Haematol"},{"issue":"10","key":"2801_CR4","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3748\/wjg.v13.i10.1628","volume":"13","author":"N Dai","year":"2007","unstructured":"Dai N, Yu YC, Ren TH, et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol, 2007,13(10):1628\u20131631","journal-title":"World J Gastroenterol"},{"key":"2801_CR5","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol, 2019,70(6):1222\u20131261","DOI":"10.1016\/j.jhep.2019.02.014"},{"issue":"28","key":"2801_CR6","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3748\/wjg.v25.i28.3753","volume":"25","author":"XQ Yang","year":"2019","unstructured":"Yang XQ, Ye J, Li X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol, 2019, 25(28):3753\u20133763","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2801_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clinre.2020.03.019","volume":"44","author":"V de L\u00e9dinghen","year":"2020","unstructured":"de L\u00e9dinghen V, Villate A, Robin M, et al. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol, 2020,44(4):480\u2013485","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"2801_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol, 2014,4(4):332\u2013346","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"2801_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","volume":"40","author":"DC Valla","year":"2016","unstructured":"Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol, 2016,40(4): 378\u2013385","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"2801_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1053\/j.gastro.2009.05.009","volume":"137","author":"R Harb","year":"2009","unstructured":"Harb R, Xie G, Lutzko C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology, 2009,137(2):704\u2013712","journal-title":"Gastroenterology"},{"issue":"6","key":"2801_CR11","first-page":"1086","volume":"10","author":"L Xiao","year":"2022","unstructured":"Xiao L, Hu L, Chu H, et al. Retrorsine Cooperates with Gut Microbiota to Promote Hepatic Sinusoidal Obstruction Syndrome by Disrupting the Gut Barrier. J Clin Transl Hepatol, 2022,10(6):1086\u20131098","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"2801_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018,15(7):397\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2801_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","volume":"159","author":"DM Chopyk","year":"2020","unstructured":"Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology, 2020,159(3):849\u2013863","journal-title":"Gastroenterology"},{"key":"2801_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-nutr-072610-145138","volume":"32","author":"HJ Wang","year":"2012","unstructured":"Wang HJ, Gao B, Zakhari S, et al. Inflammation in alcoholic liver disease. Annu Rev Nutr, 2012,32:343\u2013368","journal-title":"Annu Rev Nutr"},{"issue":"7","key":"2801_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/toxins10070298","volume":"10","author":"B Meijers","year":"2018","unstructured":"Meijers B, Farr\u00e9 R, Dejongh S, et al. Intestinal Barrier Function in Chronic Kidney Disease. Toxins (Basel), 2018,10(7):298","journal-title":"Toxins (Basel)"},{"issue":"1","key":"2801_CR16","doi-asserted-by":"publisher","first-page":"e13357","DOI":"10.1111\/asj.13357","volume":"91","author":"T Suzuki","year":"2020","unstructured":"Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim Sci J, 2020, 91(1):e13357","journal-title":"Anim Sci J"},{"issue":"3","key":"2801_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/gutjnl-2018-316906","volume":"68","author":"MB Zeisel","year":"2019","unstructured":"Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease. Gut, 2019, 68(3):547\u2013561","journal-title":"Gut"},{"issue":"7","key":"2801_CR18","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","volume":"27","author":"V Gangarapu","year":"2015","unstructured":"Gangarapu V, Ince AT, Baysal B, et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2015,27(7):840\u2013845","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"2801_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"7","key":"2801_CR20","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1478-3231.2008.01723.x","volume":"28","author":"A Farhadi","year":"2008","unstructured":"Farhadi A, Gundlapalli S, Shaikh M, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int, 2008,28(7):1026\u20131033","journal-title":"Liver Int"},{"issue":"8","key":"2801_CR21","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jn\/138.8.1452","volume":"138","author":"S Thuy","year":"2008","unstructured":"Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr, 2008,138(8):1452\u20131455","journal-title":"J Nutr"},{"issue":"6","key":"2801_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jhep.2008.01.035","volume":"48","author":"I Bergheim","year":"2008","unstructured":"Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol, 2008,48(6):983\u2013992","journal-title":"J Hepatol"},{"issue":"12","key":"2801_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med, 2010,362(12):1071\u20131081","journal-title":"N Engl J Med"},{"issue":"2","key":"2801_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jgh.13841","volume":"33","author":"Y Jin","year":"2018","unstructured":"Jin Y, Ren X, Li G, et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol, 2018,33(2):443\u2013452","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2801_CR25","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.510290615","volume":"29","author":"LD DeLeve","year":"1999","unstructured":"DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology, 1999,29(6):1779\u20131791","journal-title":"Hepatology"},{"issue":"12","key":"2801_CR26","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1586\/1744666X.2014.979792","volume":"10","author":"AH Ali","year":"2014","unstructured":"Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis. Expert Rev Clin Immunol, 2014, 10(12):1667\u20131678","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"2801_CR27","doi-asserted-by":"publisher","first-page":"e0189221","DOI":"10.1371\/journal.pone.0189221","volume":"12","author":"S Kim","year":"2017","unstructured":"Kim S, Kim GH. Roles of claudin-2, ZO-1 and occludin in leaky HK-2 cells. PLoS One, 2017,12(12):e0189221","journal-title":"PLoS One"},{"issue":"6","key":"2801_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.tiv.2005.11.006","volume":"20","author":"WC Prozialeck","year":"2006","unstructured":"Prozialeck WC, Edwards JR, Lamar PC, et al. Epithelial barrier characteristics and expression of cell adhesion molecules in proximal tubule-derived cell lines commonly used for in vitro toxicity studies. Toxicol In Vitro, 2006,20(6):942\u2013953","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"2801_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/toxsci\/kfz193","volume":"172","author":"Z Huang","year":"2019","unstructured":"Huang Z, Chen M, Wei M, et al. Liver Inflammatory Injury Initiated by DAMPs-TLR4-MyD88\/TRIF-NF\u03baB Signaling Pathway Is Involved in Monocrotaline-Induced HSOS. Toxicol Sci, 2019,172(2):385\u2013397","journal-title":"Toxicol Sci"},{"issue":"1","key":"2801_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/ijms22010202","volume":"22","author":"J Gl\u00fcck","year":"2020","unstructured":"Gl\u00fcck J, Waizenegger J, Braeuning A, et al. Pyrrolizidine Alkaloids Induce Cell Death in Human HepaRG Cells in a Structure-Dependent Manner. Int J Mol Sci, 2020,22(1):202","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2801_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0168-8278(03)00231-9","volume":"39","author":"M Chojkier","year":"2003","unstructured":"Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol, 2003, 39(3):437\u2013446","journal-title":"J Hepatol"},{"key":"2801_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cbi.2015.09.011","volume":"243","author":"M Yang","year":"2016","unstructured":"Yang M, Ruan J, Fu PP, et al. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact, 2016,243:119\u2013126","journal-title":"Chem Biol Interact"},{"issue":"19","key":"2801_CR33","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.3390\/ijms221910419","volume":"22","author":"R Teschke","year":"2021","unstructured":"Teschke R, Vongdala N, Quan NV, et al. Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update. Int J Mol Sci, 2021,22(19):10419","journal-title":"Int J Mol Sci"},{"key":"2801_CR34","doi-asserted-by":"publisher","first-page":"101117","DOI":"10.1016\/j.redox.2019.101117","volume":"22","author":"Z Huang","year":"2019","unstructured":"Huang Z, Jing X, Sheng Y, et al. (-)-Epicatechin attenuates hepatic sinusoidal obstruction syndrome by inhibiting liver oxidative and inflammatory injury. Redox Biol, 2019,22:101117","journal-title":"Redox Biol"},{"key":"2801_CR35","doi-asserted-by":"publisher","first-page":"152307","DOI":"10.1016\/j.tox.2019.152307","volume":"428","author":"Z Huang","year":"2019","unstructured":"Huang Z, Zhao Q, Chen M, et al. Liquiritigenin and liquiritin alleviated monocrotaline-induced hepatic sinusoidal obstruction syndrome via inhibiting HSP60-induced inflammatory injury. Toxicology, 2019,428: 152307","journal-title":"Toxicology"},{"issue":"17","key":"2801_CR36","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.3390\/ijms21176402","volume":"21","author":"B Allam-Ndoul","year":"2020","unstructured":"Allam-Ndoul B, Castonguay-Paradis S, Veilleux A. Gut Microbiota and Intestinal Trans-Epithelial Permeability. Int J Mol Sci, 2020,21(17):6402","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2801_CR37","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","volume":"56","author":"PD Cani","year":"2007","unstructured":"Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 2007,56(7):1761\u20131772","journal-title":"Diabetes"},{"issue":"8","key":"2801_CR38","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1136\/gutjnl-2018-316670","volume":"68","author":"L Liao","year":"2019","unstructured":"Liao L, Schneider KM, Galvez EJC, et al. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut, 2019,68(8):1477\u20131492","journal-title":"Gut"},{"issue":"7","key":"2801_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17474124.2018.1481747","volume":"12","author":"FR Ponziani","year":"2018","unstructured":"Ponziani FR, Zocco MA, Cerrito L, et al. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol, 2018,12(7):641\u2013656","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"2801_CR40","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.2527\/jas.2011-4627","volume":"90","author":"V Mani","year":"2012","unstructured":"Mani V, Weber TE, Baumgard LH, et al. Growth and Development Symposium: Endotoxin, inflammation, and intestinal function in livestock. J Anim Sci, 2012,90(5):1452\u20131465","journal-title":"J Anim Sci"},{"issue":"9","key":"2801_CR41","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1161\/01.ATV.0000081741.38087.F9","volume":"23","author":"JB Rice","year":"2003","unstructured":"Rice JB, Stoll LL, Li WG, et al. Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol, 2003,23(9):1576\u20131582","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2801_CR42","doi-asserted-by":"publisher","first-page":"633830","DOI":"10.3389\/fimmu.2021.633830","volume":"12","author":"Q Xu","year":"2021","unstructured":"Xu Q, Guo J, Li X, et al. Necroptosis Underlies Hepatic Damage in a Piglet Model of Lipopolysaccharide-Induced Sepsis. Front Immunol, 2021,12:633830","journal-title":"Front Immunol"},{"issue":"9","key":"2801_CR43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2014.106","volume":"67","author":"F Calanni","year":"2014","unstructured":"Calanni F, Renzulli C, Barbanti M, et al. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo), 2014,67(9):667\u2013670","journal-title":"J Antibiot (Tokyo)"},{"issue":"10","key":"2801_CR44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","volume":"142","author":"HL DuPont","year":"2005","unstructured":"DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers\u2019 diarrhea. Ann Intern Med, 2005,142(10):805\u2013812","journal-title":"Ann Intern Med"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-023-2801-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-023-2801-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:07:50Z","timestamp":1703772470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-023-2801-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2801"],"URL":"https:\/\/doi.org\/10.1007\/s11596-023-2801-y","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On behalf of all authors, the corresponding author states that there are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}